- Home
- QUIK vs CHRS Comparison
QUIK vs CHRS Comparison
Compare QUIK & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- CHRS
- Stock Information
- Founded
- QUIK 1988
- CHRS 2010
- Country
- QUIK United States
- CHRS United States
- Employees
- QUIK N/A
- CHRS N/A
- Industry
- QUIK Semiconductors
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QUIK Technology
- CHRS Health Care
- Exchange
- QUIK Nasdaq
- CHRS Nasdaq
- Market Cap
- QUIK 87.3M
- CHRS 84.2M
- IPO Year
- QUIK 1997
- CHRS 2014
- Fundamental
- Price
- QUIK $6.49
- CHRS $0.90
- Analyst Decision
- QUIK Strong Buy
- CHRS Buy
- Analyst Count
- QUIK 3
- CHRS 3
- Target Price
- QUIK $10.87
- CHRS $4.68
- AVG Volume (30 Days)
- QUIK 296.7K
- CHRS 1.2M
- Earning Date
- QUIK 08-12-2025
- CHRS 08-07-2025
- Dividend Yield
- QUIK N/A
- CHRS N/A
- EPS Growth
- QUIK N/A
- CHRS N/A
- EPS
- QUIK N/A
- CHRS N/A
- Revenue
- QUIK $18,768,000.00
- CHRS $272,251,000.00
- Revenue This Year
- QUIK $11.58
- CHRS N/A
- Revenue Next Year
- QUIK $40.23
- CHRS $106.56
- P/E Ratio
- QUIK N/A
- CHRS N/A
- Revenue Growth
- QUIK N/A
- CHRS 19.87
- 52 Week Low
- QUIK $4.26
- CHRS $0.66
- 52 Week High
- QUIK $13.36
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- QUIK 60.73
- CHRS 59.04
- Support Level
- QUIK $5.99
- CHRS $0.73
- Resistance Level
- QUIK $7.24
- CHRS $0.82
- Average True Range (ATR)
- QUIK 0.41
- CHRS 0.04
- MACD
- QUIK 0.07
- CHRS 0.02
- Stochastic Oscillator
- QUIK 65.13
- CHRS 88.02
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.